On November 9, 2026 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, reported that a patient with advanced liver cancer who participated in its completed Phase II study of Namodenoson has reached ten years of overall survival. The patient, whose complete response was previously reported by the Company, remains cancer-free and in good health.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This decade-long survival marks an exceptional individual outcome in advanced hepatocellular carcinoma (HCC), the most common form of liver cancer. Following the Company’s announcement of nine-year survival in November 2025, the patient’s continued well-being adds another year to this remarkable clinical story.
"Behind this ten-year milestone is a woman who continues to live well a decade after participating in our study with advanced liver cancer. For patients, families, and those of us working to develop new treatments, this is a deeply meaningful achievement," said Prof. Pnina Fishman, Chairperson and Chief Scientific Officer of Can-Fite. "Her exceptional outcome strengthens our commitment to advancing Namodenoson and evaluating its potential to provide durable clinical benefit for patients with liver cancer."
Namodenoson is currently being evaluated in Can-Fite’s ongoing randomized, double-blind, placebo-controlled pivotal Phase III study in patients with advanced HCC and underlying Child-Pugh B7 cirrhosis. As announced on September 2, 2026, overall survival across the pooled, blinded study population appeared longer than anticipated based on the study’s design assumptions, prompting the Company to evaluate earlier timing for the planned interim analysis. The study remains blinded, and the survival observation includes both Namodenoson- and placebo-treated patients; treatment-specific efficacy will be assessed through the planned analysis.
About Namodenoson
Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). Namodenoson is currently being evaluated in a pivotal Phase 3 trial for advanced liver cancer, concluded successfully a Phase 2a study in pancreatic cancer and is enrolling patients in a Phase 2b trial for the treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH). A3AR is highly expressed in diseased cells whereas low expression is found in normal cells. This differential expression may be one of the important factors that accounts for the excellent safety profile of the drug.
(Press release, Can-Fite BioPharma, NOV 9, 2026, View Source [SID1234674465])